-
Screening for pre-eclampsia by maternal factors and biomarkers at 11-13 weeks' gestation.
Tan MY, Syngelaki A, Poon LC, Rolnik DL, O'Gorman N, Delgado JL, Akolekar R, Konstantinidou L, Tsavdaridou M, Galeva S, Ajdacka U, Molina FS, Persico N, Jani JC, Plasencia W, Greco E, Papaioannou G, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;52:186-195. pdf -
Screening for pre-eclampsia at 35-37 weeks' gestation.
Panaitescu A, Ciobanu A, Syngelaki A, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;52:501-506. pdf -
Prediction and prevention of small-for-gestational-age neonates: evidence from SPREE and ASPRE.
Tan MY, Poon LC, Rolnik DL, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Greco E, Papaioannou G, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;52:52-59. pdf -
Management of pregnancies after combined screening for pre-eclampsia at 19-24 weeks' gestation.
Litwinska M, Syngelaki A, Wright A, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;52:365-372. pdf -
Fetal major cardiac defects and placental dysfunction at 11-13 weeks' gestation.
Fantasia I, Kasapoglu D, Kasapoglu T, Syngelaki A, Akolekar R, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;51:194-198. pdf -
Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE.
Tan MY, Wright D, Syngelaki A, Akolekar R, Cicero S, Janga D, Singh M, Greco E, Wright A, Maclagan K, Poon LC, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;51:743-750. pdf -
ASPRE trial: incidence of preterm pre-eclampsia in patients fulfilling ACOG and NICE criteria according to risk by FMF algorithm.
Poon LC, Rolnik DL, Tan MY, Delgado JL, Tsokaki T, Akolekar R, Singh M, Andrade W, Efeturk T, Jani JC, Plasencia W, Papaioannou G, Blazquez AR, Carbone IF, Wright D, Nicolaides KH.
Ultrasound Obstet Gynecol 2018;51:738-742. pdf -
Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin on length of stay in the neonatal intensive care unit.
Wright D, Rolnik DL, Syngelaki A, de Paco Matallana C, Machuca M, de Alvarado M, Mastrodima S, Tan MY, Shearing S, Persico N, Jani JC, Plasencia W, Papaioannou G, Molina FS, Poon LC, Nicolaides KH.
Am J Obstet Gynecol 2018;218:612.e1-612.e6. pdf -
Protocol for the prospective validation study: 'Screening programme for pre-eclampsia' (SPREE)
Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LCY.
Ultrasound Obstet Gynecol 2017;50:175-179. pdf -
First-trimester screening for pre-eclampsia: time to act.
Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:663-664. pdf -
Expanded conventional first trimester screening.
Carmichael JB, Liu HP, Janik D, Hallahan TW, Nicolaides KH, Krantz DA.
Prenat Diagn 2017;37:802-807. pdf -
Development of pre-eclampsia within 4 weeks of sFlt-1/PlGF ratio > 38: comparison of performance at 31-34 vs 35-37 weeks' gestation.
Dragan I, Wright D, Fiolna M, Leipold G, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:209-212. pdf -
Competing-risks model in screening for pre-eclampsia in twin pregnancy according to maternal factors and biomarkers at 11-13 weeks' gestation.
Francisco C, Wright D, Benkő Z, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:589-595. pdf -
ASPRE trial: performance of screening for preterm pre-eclampsia.
Rolnik DL, Wright D, Poon LCY, Syngelaki A, O'Gorman N, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:492-495. pdf -
Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia.
Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, Akolekar R, Cicero S, Janga D, Singh M, Molina FS, Persico N, Jani JC, Plasencia W, Papaioannou G, Tenenbaum-Gavish K, Meiri H, Gizurarson S, Maclagan K, Nicolaides KH.
N Engl J Med 2017;377:613-622. pdf -
Aspirin for Evidence-Based Preeclampsia Prevention trial: influence of compliance on beneficial effect of aspirin in prevention of preterm preeclampsia.
Wright D, Poon LC, Rolnik DL, Syngelaki A, Delgado JL, Vojtassakova D, de Alvarado M, Kapeti E, Rehal A, Pazos A, Carbone IF, Dutemeyer V, Plasencia W, Papantoniou N, Nicolaides KH.
Am J Obstet Gynecol 2017;217:685.e1-685.e5. pdf -
Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history.
Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, Leipold G, Akolekar R, Shearing S, De Stefani L, Jani JC, Plasencia W, Evangelinakis N, Gonzalez-Vanegas O, Persico N, Nicolaides KH.
Am J Obstet Gynecol 2017;217:585.e1-585.e5. pdf -
Impaired placentation in women with chronic hypertension that develop preeclampsia.
Panaitescu AM, Akolekar R, Kametas N, Syngelaki A, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;50:496-500. pdf -
A study protocol for the prospective validation study: Screening programme for pre-eclampsia (SPREE)
Tan MY, Koutoulas L, Wright D, Nicolaides KH, Poon LC.
Ultrasound Obstet Gynecol 2017;50:175-179. pdf -
Multicenter screening for preeclampsia by maternal factors and biomarkers at 11-13 weeks' gestation: comparison to NICE guidelines and ACOG recommendations.
O' Gorman N, Wright D, Poon LC, Rolnik DL, Syngelaki A, de Alvarado M, Carbone IF, Dutemeyer V, Fiolna M, Frick A, Karagiotis N, Mastrodima S, de Paco Matallana C, Papaioannou G, Pazos A, Plasencia W, Nicolaides KH.
Ultrasound Obstet Gynecol 2017;49:756-760. pdf